Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second-line treatments without this regimen

Oncology Letters

Volumn 4, Issue 5, 2012, Pages 1114-1118

  Ruiz Sánchez, Daniel ^a   Calero, Miguel Alaguero ^a   Sastre Heres, Alejandro José ^a   García, María Teresa Iglesias ^a   Hernandez, Miguel Angel Calleja ^b   Martinez, Fernando Martínez ^c   Peña, Jaime Díaz ^c  

^a Central University Hospital of Asturias   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Bevacizumab; Effectiveness; Glioblastoma; Irinotecan

Indexed keywords

BEVACIZUMAB; CARMUSTINE; ENZASTAURIN; IRINOTECAN; LOMUSTINE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; RECURRENT CANCER;

EID: 84866137961     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.861     Document Type: Article

References (36)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
2. Gurney JG and Kadan-Lottick N: Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol13: 160-166, 2010.
3. Brem SS, Bierman PJ, Brem H, et al: Central nervous system cancers. J Natl Compr Canc Netw 9: 352-400, 2011.
4. Laigle-Donadey F andDelattre JY: Glioblastoma in the elderly. Geriatr Psychol Neuropsychiatr Vieil 9: 101-106, 2011 (In French).
5. Baldi I, Huchet A, Bauchet L and Loiseau H: Epidemiology of glioblastoma. Neurochirurgie 56: 433-440, 2010.
6. Bauchet L, Mathieu-Daudé H, Fabbro-Peray P, et al; Société Française de Neurochirurgie (SFNC); Club de Neuro-Oncologie of the Société Française de Neurochirurgie (CNO-SFNC); Société Française de Neuropathologie (SFNP); Association des Neuro-Oncologues d'Expression Française (ANOCEF): Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol 12: 725-735, 2010.
7. Deorah S, Lynch CF, Sibenaller ZA and Ryken TC: Trends in brain cancer incidence and survival in the United States: surveillance, epidemiology, and end results program, 1973 to 2001. Neurosurg Focus 20: E1, 2010.
8. HUCA tumour register. 2008 Annual Report. Hospital Universitario Central de Asturias and Instituto Universitario Oncológico, Principality of Asturias, 2008. ISSN 1138-8501. http://10.15.65.11/huca/web/contenidos/servicios/rt/rt2008/rt2008.pdf. Accesed January 21, 2012.
9. Stupp R, Mason WP, van den Bent MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolamide for glioblastoma. N Engl J Med352: 987-996, 2005.
10. Stupp R, Hegi ME, Mason WP, et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
11. Lacroix M, Abi-Said D, Fourney DR, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95: 190-198, 2001.
12. Mineo JF, Bordron A, Baroncini M, et al: Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir (Wien) 149: 245-253, 2007.
13. Brandes AA, Tosoni A, Franceschi E, Reni M, Gatta G and VechtC: Glioblastoma in adults. Crit Rev Oncol Hematol 67: 139-152, 2008.
14. Maxwell M, Naber SP, Wolfe HJ, Hedley-Whyte ET, Galanopoulos T, Neville-Golden J and Antoniades HN: Expression of angiogenic growth factor genes in primary human astrocytomas may contribute to their growth and progression. Cancer Res 51: 1345-1351, 1991.
15. Takahasi JA, Fukumoto M, Igarashi K, Oda Y, Kikuchi H and Hatanaka M: Correlation of Basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 76: 792-798, 1992.
16. Folkman J: Tumor angiogenesis: Therapeutic implications. NEngl J Med 285: 1182-1186, 1971.
17. Friedman HS, Prados MD, Wen PY, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. JClin Oncol 27: 4733-4740, 2009.
18. Norden AD, Young GS, Setayesh K, et al: Bevacizumab for recurrent malignant gliomas, efficacy, toxicity and patterns of recurrence. Neurology 70: 779-787, 2008.
19. Kreisl TN, Kim L, Moore K, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27: 740-745, 2009.
20. Vredenburgh JJ, Desjardins A, Herndon JE, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-4729, 2007.
21. Zuniga RM, Torcuator R, Jain R, et al: Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. JNeurooncol91: 329-336, 2009.
22. Stark-Vance V: Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol 7 (Suppl): 369, abstr342, 2005.
23. Raval S, Hwang S and Dorsett L: Bevacizumab and irinotecan in patients with recurrent glioblastoma multiforme. J Clin Oncol 25 (Suppl): abstr 2078, 2007.
24. Vredenburgh JJ, Desjardins A, Herndon JE II, et al: PhaseII trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253-1259, 2007.
25. Ali SA, McHayleh WM, Ahmad A, et al: Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg 109: 268-272, 2008.
26. Bokstein F, Shpigel S and Blumenthal DT: Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112: 2267-2273, 2008.
27. Cloughesy TF, Prados MD, Wen PY, et al: A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment refractory glioblastoma (GBM). J Clin Oncol 26 (Suppl): abstr2010b, 2008.
28. Desjardins A, Reardon DA, Herndon JE II, et al: Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 14: 7068-7073, 2008.
29. Guiu S, Taillibert S, Chinot O, et al: Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study. Rev Neurol (Paris) 164: 588-594, 2008 (In French).
30. Gilbert MR, Wang M, Aldape K, et al: RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J Clin Oncol 27 (Suppl): abstr2011, 2009.
31. Nghiemphu PL, Liu W, Lee Y, et al: Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72: 1217-1222, 2009.
32. Poulsen HS, Grunnet K, Sorensen M, et al: Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol 48: 52-58, 2009.
33. Cloughesy T, Vredenburgh JJ, Day B, et al: Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J Clin Oncol 28 (Suppl): abstr2008, 2010.
34. Desjardins A, Vredenburgh JJ, Reardon DA, et al: Longterm survival from the initial trial of bevacizumab and irinotecan. J Clin Oncol 28 (Suppl): abstr 2045, 2010.
35. Cohen MH, Shen YL, Keegan P and Pazdur R: FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14: 1131-1138, 2009.
36. Seiz M, KraVt U, Freyschlag CF, et al: Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. J Cancer Res Clin Oncol 136: 1691-1695, 2010.